Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 1/20 | 0.59 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.59 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 7/20 | 0.47 |
| ▸ | TUBB | P07437 | 7/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 7/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 7/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 7/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 7/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 7/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 7/20 | 0.47 |
| ▸ | TUBB8 | Q3ZCM7 | 7/20 | 0.47 |
| ▸ | TUBA3E | Q6PEY2 | 7/20 | 0.47 |
| ▸ | TUBA1A | Q71U36 | 7/20 | 0.47 |
| ▸ | TUBA1C | Q9BQE3 | 7/20 | 0.47 |
| ▸ | TUBB6 | Q9BUF5 | 7/20 | 0.47 |
| ▸ | TUBB2B | Q9BVA1 | 7/20 | 0.47 |
| ▸ | TUBB1 | Q9H4B7 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7680891 | 0.88 | TUBB4A (0.46) | CXCL8AKR1B1PTGS1PTGS2GLO1 | |
| SCHEMBL7685205 | 0.87 | CXCL8 (0.63) | CXCL8AKR1B1PTGS1PTGS2GLO1 | |
| SCHEMBL7678041 | 0.80 | CXCL8 (0.72) | CXCL8AKR1B1PTGS1PTGS2GLO1 | |
| SCHEMBL11812553 | 0.78 | KDM4E (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL8732112 | 0.78 | SMPD1 (0.56) | CXCL8AKR1B1PTGS1PTGS2GLO1 | |
| SCHEMBL11808828 | 0.77 | ALDH1A1 (0.46) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL2237360 | 0.77 | PTGS2 (0.77) | CXCL8AKR1B1PTGS1PTGS2GLO1 | |
| SCHEMBL11486705 | 0.77 | NPC1 (0.51) | CXCL8AKR1B1PTGS1PTGS2GLO1 | |
| SCHEMBL8732029 | 0.76 | PTGS1 (0.67) | CXCL8AKR1B1PTGS1PTGS2GLO1 | |
| SCHEMBL8726489 | 0.76 | PTGS2 (0.62) | CXCL8AKR1B1PTGS1PTGS2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6455703-B2 | ADMINISTERING EFFECTIVE AMOUNT OF 1,3,6-TRIHYDRO-6-AZA-3-OXAPENTALEN-2-ONE DERIVATIVE TO THE PATIENT FOR INDUCING OR PROMOTING APOPTOSIS AND FOR ARRESTING UNCONTROLLED NEOPLASTIC CELL PROLIFERATION | CELL PATHWAYS, INC. | 2002-09-24 | — | — | US | disclosed |
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | OSI PHARMACEUTICALS, INC. | 2001-12-13 | — | — | US | disclosed |
| US-6160003-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-5939417-A | 1,3,6-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | CELL PATHWAYS INC (US) | 1999-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051651-A1 | 1,3,6,-trihydro-6-aza-3-oxapentalen-2-one derivatives for the treatment of neoplasia | MALT1, VHL, CDKN1A | CXCL8 3828/4885AKR1B1 346/4885PTGS1 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.